Summary:
Scientists have made significant progress in developing personalized cancer vaccines that train the immune system to target individual tumors, paving the way for more effective cancer therapies.
Summary:
At JPM25, experts predicted a rise in megamergers, a shift to smaller Series A funding rounds, and potential consolidation among struggling small biotechs due to funding challenges.
Summary:
Researchers have developed a CRISPR-based diagnostic test capable of rapidly detecting multiple infectious diseases with high accuracy, potentially transforming disease diagnosis and management.
Summary:
As President Trump begins his second term, technology sectors like artificial intelligence and space exploration anticipate favorable policies, while environmental and biomedical sciences face potential funding cuts and regulatory rollbacks.
Summary:
2025 kicks off with robust pharma M&A activity, highlighted by J&J’s $14.6B intra-cellular deal. The industry holds $1.3T in deal potential, though high premiums and margin pressures may impact future transactions.
